Hikma Pharmaceuticals (LON:HIK) had its price target lifted by equities research analysts at JPMorgan Chase & Co. from GBX 1,700 ($22.21) to GBX 1,800 ($23.52) in a research report issued to clients and investors on Tuesday, ThisIsMoney.Co.Uk reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 5.34% from the stock’s previous close.

A number of other analysts have also recently commented on HIK. Morgan Stanley reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 13th. Jefferies Financial Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Friday, November 15th. Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, November 7th. Peel Hunt reiterated a “hold” rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 27th. Finally, Barclays reiterated an “equal weight” rating on shares of Hikma Pharmaceuticals in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of GBX 1,798.33 ($23.50).

Shares of HIK stock opened at GBX 1,901.50 ($24.85) on Tuesday. The stock has a market cap of $4.61 billion and a P/E ratio of 12.78. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The company has a fifty day moving average price of GBX 1,952.47 and a two-hundred day moving average price of GBX 1,882.28. Hikma Pharmaceuticals has a one year low of GBX 1,491.50 ($19.49) and a one year high of GBX 2,212 ($28.90).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

Further Reading: What is FinTech?

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.